Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

Russia will start the production of its <keyword id="8904563" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccine">COVID-19 vaccine</keyword> within two weeks, the country's <keyword id="9682335" type="UNKNOWN" weightage="20" keywordseo="health-minister-mikhail-murashko">health minister Mikhail Murashko</keyword> said. "First of all, the production facilities in Russia will be oriented towards the domestic market, to meet the need of our citizens," Murashko said during a news conference on Wednesday, Xinhua news agency reported. Russia will offer the vaccine to other countries when it has sufficient amounts, the minister said, adding that foreign nations' doubts about the effectiveness of the vaccine are unfounded. The platform where the vaccine was created has been thoroughly studied and its authors have accumulated a sufficient amount of scientific data to guarantee its safety, he added. The world's first registered vaccine against the novel coronavirus was announced by President Vladimir Putin on Tuesday during an online meeting with government officials. The vaccine, named Sputnik V, was developed by the Gamaleya National Center of Epidemiology and Microbiology, alongside <keyword id="9667533" type="COMPANY" weightage="20" keywordseo="the-russian-direct-investment-fund">the Russian Direct Investment Fund</keyword>. Russia plans to produce at least five million doses of the vaccine a month from December through January, according to <keyword id="9748344" type="PERSON" weightage="20" keywordseo="alexander-gintsburg">Alexander Gintsburg</keyword>, director of <keyword id="9748343" type="COMPANY" weightage="20" keywordseo="the-gamaleya-national-research-center">the Gamaleya National Research Center</keyword>. He said that the center is also preparing documents to obtain permission to test the vaccine on children. The vaccine for children will be the same as the one for adults, but will likely be administered in a different dosage, requiring additional testing, Gintsburg added. So far, Russia has tallied a total of 902,701 COVID-19 cases, including 15,260 deaths and 710,298 recoveries. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-today-britannia-hero-motocorp-ashok-leyland-mm-financial-indiabulls-housing-and-more/articleshow/77516263.cms" data-type="tilCustomLink">Top stocks to watch today— Britannia, Hero MotoCorp, Ashok Leyland, M&amp;M Financial, Indiabulls Housing and more</a> <a href="https://www.businessinsider.in/tech/news/it-only-takes-50-tweets-to-find-a-troll-on-twitter/articleshow/77512151.cms" data-type="tilCustomLink">It only takes 50 tweets to find a troll on Twitter</a>

Russia to begin COVID-19 vaccine production within 2 weeks

Moscow, Aug 16 (IANS) The third stage of the research on the world's first registered vaccine against the novel coronavirus, called Sputnik V, may begin in 7-10 days, a report has said. According to the Tass news agency, several tens of thousands of people are expected to take part in this research of the vaccine created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology of the Russian Health Ministry. "On Monday, we will present the first version of the protocol on post-registration research," Alexander Gintsburg, Director of the Gamaleya National Research Center, was quoted as saying to Tass. "Given this great interest and attention of the public and the press, I think that the Health Ministry won't delay the process and will approve the protocol within a week. So, I believe within seven or ten days at maximum everything will begin," Gintsburg added. Gintsburg said several tens of thousands of people were expected to be involved by the third stage. The research will be conducted in the Moscow Region. Meanwhile, Russia has begun production of the first batch of vaccines against Covid-19, its health ministry said in a statement released on Saturday. The world's first registered vaccine against the novel coronavirus was announced by President Vladimir Putin on Tuesday during an online meeting with government officials. The vaccine Sputnik V, which is named after the space satellite launched by Moscow in 1957, was created by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology, alongside the Russian Direct Investment Fund. Russia will offer the vaccine to other countries once its own citizens are vaccinated, Health Minister Mikhail Murashko said Wednesday, adding that doubts over the effectiveness of the vaccine are unfounded. So far, Russia has tallied a total of 917,884 cases, with 15,617 deaths and 729,411 recoveries. --IANS bu/

3rd stage of Russia's Covid-19 vaccine may begin in 7-10 days

Moscow, Jun 17 (AP) Clinical trials of a Russian coronavirus vaccine have started Wednesday, the Health Ministry said in a statement. Two forms of the vaccine developed by the Moscow-based Gamaleya research institute - liquid and powder for injections - will be tested on two groups of volunteers, 38 people each, the statement said. The participants will be isolated in two Moscow hospitals. "Running clinical trials in the midst of a pandemic is a unique situation. So unprecedented measures have been taken - all potential participants of the trial ... spent two weeks (quarantined) in a sanatorium for observation," the ministry said, adding that the first injections are scheduled for Thursday and Friday. The Gamaleya institute made headlines last month when its director, professor Alexander Gintsburg, made a statement that he and other researchers had tried the vaccine on themselves before the start of human studies. He didn't clarify how many people injected themselves with the substance, but told the Interfax news agency that no one experienced any side effects: "Everyone is alive and well and cheerful." In comments to RIA Novosti, Gintsburg insisted that he and others hadn't intended to test the vaccine - they were merely looking to "protect themselves (from the virus) with the vaccine." "It's not a trial. It's self-defense in order for us to continue working (on the vaccine). Losing a staffer (to the virus) would delay the work. Knowing what they're developing, they consciously took this step. And so did I," Gintsburg said. Gintsburg's comments sparked criticism in the Russian medical community. The country's Association of Clinical Research Organizations issued a statement condemning the actions of the researchers as a "crude violation of the very foundations of clinical research, Russian law and universally accepted international regulations." The association accused Russian authorities of rushing researchers to finish clinical trials of COVID-19 vaccines, saying "an unattainable bar has been set. Many scientists understand that, yet they got involved in the crazy race, hoping to please those in power." Days before Gintsburg revealed trying the vaccine, Kremlin spokesman Dmitry Peskov extended "words of admiration" to scientists testing the vaccine on themselves. "Let's not name the facility, the people. But these are people that are fanatics in what they do in the best sense of the word," Peskov told the Kommersant newspaper in an interview in mid-May. According to Russian media, at least seven research facilities are currently working on coronavirus vaccines. (AP) RS RS

Russia starts clinical trials of COVID-19 vaccine

Moscow, <keyword id="6358826" type="LOCATION" weightage="20" keywordseo="Russia">Russia</keyword>'s <keyword id="9739494" type="UNKNOWN" weightage="20" keywordseo="sputnik-v-vaccine">Sputnik V vaccine</keyword> demonstrated efficacy of 91.6 per cent against <keyword id="8763838" type="UNKNOWN" weightage="20" keywordseo="covid-19">Covid-19</keyword>, according to interim results of phase 3 trials published in the journal The Lancet. Data on 19,866 volunteers were included in the efficacy analysis - 14,964 of whom received the <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> and 4,902 the placebo. The calculation is based on the analysis of 78 confirmed cases of Covid-19 identified in the placebo group (62 cases) and in the vaccine group (16 cases). Efficacy in the elderly group of 2,144 volunteers over 60 years old was 91.8 per cent and did not differ statistically from the 18-60 group, said the study, adding that Sputnik V provided full protection against severe cases of Covid-19. Registered by Russia on August 11, 2020 Sputnik V became the world's first coronavirus vaccine. The vaccine was developed by the Gamaleya National Research Center of Epidemiology and Microbiology. "The publication of internationally peer reviewed data on Sputnik V's clinical trial results is a great success in the global battle against the Covid-19 pandemic," Alexander Gintsburg, Director of the Gamaleya Research Institute of Epidemiology and Microbiology, said in a statement. The vaccine is based on a platform of human adenoviral vectors. "Several vaccines have already been created based on human adenoviruses and this tool is one of the most promising for development of new vaccines in the future," Gintsburg said. The data in the new study showed 70 episodes of serious adverse events not related to Covid-19 in 68 study participants -- in 45 volunteers from the vaccine group and 23 volunteers from the placebo group. None of these events were associated with the vaccination, as stated by an independent data monitoring committee. Sputnik V is already registered in several countries including Russia, Belarus, <keyword id="11015" type="LOCATION" weightage="20" keywordseo="Serbia">Serbia</keyword>, Argentina, Bolivia, Algeria, Venezuela, Paraguay, Turkmenistan, Hungary, the UAE, Iran, Republic of Guinea, Tunisia and Armenia, said the makers of the vaccine In the first week of February, vaccination with Sputnik V is starting in several countries including Bolivia, Kazakhstan, Armenia, Algeria, Venezuela and Iran. The two-dose regimen of Sputnik V is administered 21 days apart. SEE ALSO: <a href="https://www.businessinsider.in/business/news/mukesh-ambani-ratan-tata-and-anand-mahindra-might-come-together-for-indias-new-national-hydrogen-mission/articleshow/80645570.cms">Mukesh Ambani, Ratan Tata, and Anand Mahindra might come together for India’s new National Hydrogen Mission</a> <a href="https://www.businessinsider.in/stock-market/news/indigo-paints-shares-listed-at-2607-which-is-at-75-premium-to-the-set-price-band-at-1488-1490-per-share/articleshow/80643645.cms">India’s fifth-largest paint maker Indigo Paints IPO lists at 75% premium over the issue price</a>

Sputnik V vaccine shows 91.6% efficacy in phase 3 trials, says Lancet

<keyword id="6356806" type="LOCATION" weightage="20" keywordseo="moscow">Moscow</keyword>, <keyword id="6358826" type="LOCATION" weightage="20" keywordseo="Russia">Russia</keyword>'s <keyword id="9739267" type="PERSON" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> is likely to offer two-year-long protection against Covid-19, Alexander Gintsburg, the head of the vaccine's developer, Gamaleya National Research Center for Epidemiology and Microbiology, has claimed. "So far, I can only make suggestions, because more experimental data is needed. Our vaccine was created on the platform also used for the Ebola vaccine," he was quoted as saying to the Soloviev Live channel on YouTube by TASS News Agency on Saturday. "Experimental data received at that point demonstrate that a similar vaccine would offer protection for two years, maybe more." According to the Russian scientist, Sputnik V is effective in 96% of cases. The remaining four percent of vaccinated persons will have a mild form of the disease with runny nose, cough and slight fever, but their lungs won't be affected. Registered by Russia on August 11, Sputnik V became the world's first coronavirus vaccine. The vaccine was developed by the Gamaleya National Research Center of Epidemiology and Microbiology. Its post-registration trials began in Moscow on September 7, with volunteers receiving the first vaccine on September 9. A total of 40,000 people are involved in the programme. According to interim research results, the efficacy of the Sputnik V vaccine exceeds 95% on the 42nd day after the <keyword id="6700138" type="UNKNOWN" weightage="20" keywordseo="first-dose">first dose</keyword>, provided that a patient receives the second dose. On December 2, Russian President <keyword id="43440" type="PERSON" weightage="20" keywordseo="Vladimir-Putin">Vladimir Putin</keyword> ordered to organise a nationwide vaccination. SEE ALSO: <a href="https://www.businessinsider.in/science/space/news/dos-and-donts-during-solar-eclipse-surya-grahan/articleshow/76436997.cms">The do’s and don’ts of a Solar Eclipse — here what you need to know to protect yourself</a> <a href="https://www.businessinsider.in/science/space/news/solar-eclipse-december-2020-time-date-everything-you-need-to-know/articleshow/79697355.cms">The total solar eclipse and its 'diamond rings' won't be visible in India on December 14</a>

Sputnik V Covid vax likely to offer 2-year protection: Developers

<ul class="summary-list"><li>A Russian health official told citizens they shouldn't drink <keyword id="6359858" type="UNKNOWN" weightage="60" keywordseo="alcohol">alcohol</keyword> two weeks before and six weeks after getting the COVID-19 <keyword id="24209" type="PERSON" weightage="60" keywordseo="vaccine">vaccine</keyword>.</li><li>There's no evidence suggesting any relationship between alcohol consumption and vaccine efficacy, although booze has been found to weaken the immune system.</li><li>An American expert said the Russian recommendation was too extreme and may deter people from getting the vaccine.</li></ul>Russians are outraged following a health official's warning that COVID-19 vaccine recipients should abstain from drinking alcohol in the weeks before and after their shots, <a href="https://www.reuters.com/article/health-coronavirus-russia-vaccine-alcoho/dont-mix-sputnik-vaccine-with-alcohol-says-russian-official-some-recoil-idUSKBN28J239">Reuters</a> reported Wednesday.Anna Popova, head of <keyword id="6358826" type="LOCATION" weightage="60" keywordseo="Russia">Russia</keyword>'s consumer health watchdog, went on national radio Tuesday to tell citizens they should not imbibe for two weeks before their first injection of the Sputnik V vaccine. Vaccine recipients should stay sober for an additional six weeks after that to ensure a strong immune response, she added. There are 21 days between the two Sputnik shots."I reckon the stress on the body of giving up alcohol, especially during what is a festive period, would be worse than the (side effects of the) vaccine and its alleged benefits," Moscow resident Elena Kriven told Reuters.However, both Russian and American vaccine experts said Popova's advice was too extreme. Alexander Gintsburg, the developer of Russia's vaccine, <a href="https://twitter.com/sputnikvaccine/status/1336636825805451266">tweeted from the Sputnik V account</a> that "one glass of champagne won't hurt anyone."In another <a href="https://twitter.com/sputnikvaccine/status/1336636436519530496">tweet</a>, Gintsburg recommended abstaining from alcohol use three days before and after each injection of any vaccine, not just Sputnik.But William Moss, executive director of the International Vaccine Access Center at Johns Hopkins University, said there's no data to support such advice."There's no evidence that, if you have one beer or a glass of wine a couple days after you get your vaccine, that's going to interfere with your immune response or protection following the vaccine," Moss said. "When that point is stated in such an extreme way, I think it's actually damaging to public health."<h2>Excessive alcohol use can weaken your immune system</h2>Chronic and excessive alcohol use - eight or more drinks a week for women and 15 or more drinks a week for men, according to the <a href="https://www.cdc.gov/alcohol/pdfs/excessive_alcohol_use.pdf">CDC</a> - can have <a href="https://www.insider.com/does-alcohol-weaken-the-immune-system">a number of deleterious effects</a> on the body, Moss said.Research has shown that<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4590612/"> drinking alcohol affects the gut microbiome</a> and may damage the immune cells that line the intestines, which serve as the first line of defense against viruses and bacteria. Another <a href="https://www.sciencedirect.com/science/article/abs/pii/S0741832914201868?via%3Dihub">study</a> found that binge drinking depletes the infection-fighting abilities of certain white blood cells in the hours after intoxication.Having a strong immune system is especially important during a pandemic, so it may be wise to cut back on alcohol for that reason. But there's not much, if any, research that specifically looked at interactions between vaccines and alcohol - likely because most vaccines are administered to children, Moss pointed out.<h2>We don't know much about the Russian vaccine's efficacy</h2>Russia <a href="https://www.businessinsider.com/russia-approves-coronavirus-vaccine-experts-say-needs-more-testing-2020-8">approved Sputnik V for public use</a> in August, but has yet to release any data from phase 3 trials that would determine the efficacy of the vaccine.The Sputnik V vaccine is an <a href="https://www.businessinsider.com/leading-us-coronavirus-vaccines-how-they-work-compare-2020-10">adenovirus vector vaccine</a>, which piggybacks a piece of the <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> on an inactive version of a less harmful virus. AstraZeneca and Johnson &amp; Johnson's vaccine candidates use a similar technology.On November 11 - two days after Pfizer-BioNTech announced promising results of their vaccine trials - the Russian government announced in a <a href="https://sputnikvaccine.com/newsroom/pressreleases/the-first-interim-data-analysis-of-the-sputnik-v-vaccine-against-covid-19-phase-iii-clinical-trials-/">press release</a> that Sputnik V was 92% effective after the second dose. However, they have yet to release complete, peer-reviewed data from phase 1 and 2 trials, creating an air of secrecy around the vaccine.

Russians have been told not to drink for 2 months after getting the COVID-19 vaccine

<ul class="summary-list"><li><keyword id="6358826" type="LOCATION" weightage="60" keywordseo="Russia">Russia</keyword> says it will start mass producing its leading <keyword id="1754604" type="PERSON" weightage="60" keywordseo="coronavirus">coronavirus</keyword> vaccine prototype in September.</li><li>The safety and efficacy of this vaccine has been heavily doubted, however, with its developers accused of rushing through safety trials to please the Kremlin, which is keen to win the global vaccine race.</li><li>The researchers said they trialed the vaccine on themselves to speed through human trials. A leading Russian scientific association called it a "crude violation of the very foundations of clinical research."</li><li>The Kremlin has portrayed Russia as a pandemic success story, despite accusations of fabricated data and a cover-up. President Vladimir Putin has also <a href="https://www.themoscowtimes.com/2020/06/14/putin-criticizes-us-coronavirus-response-says-protests-show-deep-seated-internal-crises-a70565">mocked</a> the <a href="https://www.businessinsider.com/bill-gates-coronavirus-crisis-us-response-criticism-2020-7">US response</a> to its outbreak.</li><li>A top Russian official likened the vaccine race to the Space Race during the Cold War, telling <a href="https://edition.cnn.com/2020/07/28/europe/russia-coronavirus-vaccine-approval-intl/index.html">CNN</a>: "Americans were surprised when they heard Sputnik's beeping. It's the same with this vaccine. Russia will have got there first."</li></ul>Russia says it will start mass-producing its coronavirus vaccine next month, despite widespread reports that scientists rushed through tests and injected themselves with the prototype to speed up the process.<a href="https://www.businessinsider.com/coronavirus-vaccine-timeline-what-to-watch-leading-research-2020-3">More than 100 vaccines</a> are being developed around the world, but only four — <a href="https://www.businessinsider.com/coronavirus-vaccine-timeline-what-to-watch-leading-research-2020-3?r=US&amp;IR=TIR=T">from Moderna, AstraZeneca, SinoVac, and Pfizer</a> — have entered phase-3 mass human trials, <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">according to the World Health Organization</a> (WHO).Now Russia claims that a Russian vaccine will be first to hit the market and administered to a population. The WHO currently recognizes two Russian vaccine trials, but says they are both still in phase 2 trials."We are very much counting on starting mass production in September," Russian trade minister Denis Manturov <a href="https://tass.com/society/1185053">told the state-run TASS news agency</a> on Monday, referring to a vaccine developed by the Gamaleya National Research Center of Epidemiology and Microbiology.Russia appears to see the global race for a coronavirus vaccine as a competition with the US, with the head of the Russian Direct Investment Fund — which <a href="https://rdif.ru/Eng_COVID-19/">finances domestic vaccine projects</a> — likening it to the Space Race between the US and Soviet Union during the Cold War."Americans were surprised when they heard Sputnik's beeping. It's the same with this vaccine. Russia will have got there first," Kirill Dmitriev <a href="https://edition.cnn.com/2020/07/28/europe/russia-coronavirus-vaccine-approval-intl/index.html">told CNN</a>.<a href="https://www.nytimes.com/2020/08/02/world/europe/russia-trials-vaccine-October.html"><div type="image" title="Moderna coronavirus vaccine trial participant" height="1908" width="3817" msid="77352922" hostid="261"></div></a>However, the trial vaccine has drawn heavy skepticism from medical professionals both inside and outside Russia.Scientists working on the Gamaleya vaccine were criticized in late May after reporting that they had taken <a href="https://interfax.com/newsroom/top-stories/68759/?sphrase_id=2105">the highly unusual step of injecting themselves with the trial vaccine</a> in an apparent attempt to speed up human trials.The center's director, Alexander Gintsburg, <a href="https://interfax.com/newsroom/top-stories/68759/?sphrase_id=2105">told Russian state news agency Interfax</a> on May 22 that the vaccine appeared to work and that "everyone is safe and sound and happy."He also said that the researchers, including himself, had injected themselves with the prototype, not to use as a test, but "to protect themselves in order to be able to work on this development amid the pandemic."But Russia's Association of Clinical Research Organizations said the step was a "crude violation of the very foundations of clinical research, Russian law, and universally accepted international regulations," <a href="https://apnews.com/0fe4b369a157867d993d65299763fcb0">according to the Associated Press</a> (AP).<div type="image" title="MOSCOW, RUSSIA - JULY 7, 2020: Russia's President Vladimir Putin meets with Maxim Akimov, Chairman of the Management Board of Russian Post, at the Moscow Kremlin. Alexei Nikolsky/Russian Presidential Press and Information Office/TASS (Photo by Alexei Nikolsky\TASS via Getty Images)" height="1861" width="3721" msid="77352927" hostid="261"></div>The association added that Gamaleya was rushing through "the crazy race" to find a vaccine "hoping to please those in power," the AP reported.Dr. Anthony Fauci, the director of the US National Institute of Allergy and Infectious Diseases, has also expressed concern about the pace of Russia's projects."I do hope that the ... Russians are actually testing the vaccine before they are administering the vaccine to anyone," Fauci said in a congressional meeting last week, <a href="https://www.nytimes.com/2020/08/02/world/europe/russia-trials-vaccine-October.html">according to The New York Times</a>.Inside Russia, state-run media and the Kremlin are peddling the narrative that Russia is pandemic success story, despite reports it is <a href="https://www.businessinsider.com/russia-registered-60-per-cent-coronavirus-deaths-moscow-other-causes-2020-5">manipulating</a> or <a href="https://www.businessinsider.com/coronavirus-russia-doctors-say-government-is-covering-up-cases-2020-3">covering up case statistics</a>, and denying medical <a href="https://www.hrw.org/news/2020/06/15/russia-health-workers-face-retaliation-speaking-out">staff sufficient personal protective equipment (PPE)</a>. President Vladimir Putin has also <a href="https://www.themoscowtimes.com/2020/06/14/putin-criticizes-us-coronavirus-response-says-protests-show-deep-seated-internal-crises-a70565">mocked</a> the US response to the coronavirus pandemic.<a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines"></a>Despite Russia's purported success at developing a vaccine, <a href="https://edition.cnn.com/2020/07/16/politics/russia-cyberattack-covid-vaccine-research/index.html">the US, UK, and Canada last month accused</a> Russia of being behind attempts to hack their top coronavirus research centers "to steal valuable intellectual property."<div type="image" title="vaccine" height="1694" width="3388" msid="77352934" hostid="261"></div>One other vaccine in Russia, which is monitored by the WHO, is also nearing approval, according to the government. Deputy Prime Minister Tatyana Golikova <a href="https://tass.com/russia/1184939">said this week</a> that the Vektor State Research Center of Virology and Biotechnology will start mass producing its vaccine in November.In late May, Russian health minister Mikhail Murashko had said the Vektor vaccine could be ready to go by the end of July.But experts have poured cold water on that claim since."Of course, you can create a prototype vaccine during such a brief period of time," Vitaly Zverev, head of the molecular technology department at the Mechnikov Research Institute of Vaccines in Moscow, <a href="https://www.rferl.org/a/moscow-vaccine-claim-questioned-as-researchers-press-forward-in-race-against-coronavirus/30645856.html">told the Russian-language network Current Time</a>."But it is impossible to have it properly tested. Hence, it would be premature to say that a mass vaccination will be launched in July.""This cannot be tested in a few weeks or even months. It is impossible to complete this colossal amount of work in four months. Some things simply cannot be sped up."

Russia says it will start mass-producing its coronavirus vaccine next month — as scientists say developers rushed through tests and injected themselves to shorten human trials

Russia's National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund on Wednesday announced that the <keyword id="9739267" type="UNKNOWN" weightage="20" keywordseo="Sputnik-V">Sputnik V</keyword> vaccine, the world's first registered vaccine against coronavirus created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy. <div type="Article" hostid="261" msid="79130097" title="Pfizer’s COVID-19 vaccine is 90% effective in preventing coronavirus in those who haven’t been infected ever before, shows data from latest trials" mstype="2" mssubtype="0"></div> Currently Sputnik V Phase III clinical trials are approved and are undergoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India. A separate detailed study of the vaccine's safety and immunogenicity for elderly people is also being conducted. The confirmation is based on the first interim data from the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers. The trials evaluated efficacy among over 16,000 volunteers who received the vaccine or placebo 21 days after the first injection. As a result of a statistical analysis of 20 confirmed cases of coronavirus, the case split between vaccinated individuals and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92 per cent after the second dose. Separately, in September the vaccine was first administered to a group of volunteers from the "red zones" of the Russian hospitals. The observation of additional 10,000 vaccinated volunteers representing medics and other high-risk groups under the civil use of the vaccine out of clinical trials also confirmed the vaccine's efficacy rate of over 90 per cent. The data received will be published by Gamaleya Center researchers in one of the world's leading peer-reviewed medical academic journals following an independent valuation of the data by leading epidemiology experts. Following the completion of Phase III clinical trials of the Sputnik V vaccine, Gamaleya Center will provide access to the full clinical trial report. As of November 11, as part of the clinical trials in Russia's 29 medical centres, more than 20,000 volunteers were vaccinated with the first dose and over 16,000 volunteers with the first and the second dose of the vaccine. In addition, as of November 11, no unexpected adverse events were identified as part of the research. Some of those vaccinated had short-term minor adverse events such as pain at the injection site, flu-like syndrome, including fever, weakness, fatigue, and headache. During the clinical trials, the safety of the vaccine is constantly being monitored; information is analysed by the Independent Monitoring Committee comprising of leading Russian scientists. Collection, quality control and data processing is conducted in line with the ICH GCP standards and involves active participation of Moscow's Health Department and Crocus Medical, the contract research organization (CRO). Observation of the study participants will continue for six months after which the final report will be presented. The research data will be provided by RDIF to the national regulators of countries interested in purchasing the Russian vaccine in order to streamline the registration process. Mikhail Murashko, Minister of Health of the Russian Federation said that the use of the vaccine and the results of clinical trials demonstrate that it is an efficient solution to stop the spread of the coronavirus infection, a preventive healthcare tool, and this is the most successful path to defeat the pandemic. Alexander Gintsburg, Gamaleya Center Director: "The publication of the interim results of the post-registration clinical trials that convincingly demonstrate Sputnik V vaccine's efficacy gives way to mass vaccination in Russia against Covid-19 in the coming weeks. Thanks to the production scale up at new manufacturing sites, Sputnik V vaccine will soon be available for a wider population. This will break the current trend and lead to an eventual decrease in Covid-19 infection rates, first in Russia, then globally." Denis Logunov, Gamaleya Center Deputy Director said that positive interim results of Phase III give reasons to expect a successful outcome of Sputnik V clinical trials. "We will continue to process and analyse all the data and look to the future with optimism, expecting that results of our work will help end the pandemic sooner." Kirill Dmitriev, CEO, Russian Direct Investment Fund: "Sputnik V is the first registered vaccine against Covid-19 in the world, the vaccine is based on a safe and effective platform of human adenoviral vectors. More and more countries are recognising the human adenoviral vector platform and plan to include these vaccines, as the most studied and known, in their respective national vaccine portfolio. I would also like to stress the importance of international cooperation and close partnership among vaccine-developing states." He added, "Vaccines should be above politics. The world needs a diversified portfolio of high-quality vaccines with Sputnik V, based on the well-tested human adenoviral vector platform, being an important element of it." The safety of vaccines based on human adenoviruses was confirmed in more than 75 international publications and more than 250 clinical trials conducted during the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953). Adenovirus vectors are genetically modified viruses of the regular flu that cannot reproduce in a human body. When Sputnik V vaccine is used, the coronavirus itself does not enter the body as the vaccine only contains genetic information about part of its outer protein coat, the so-called "spikes" forming its crown. This completely eliminates the possibility of getting infected as a result of vaccination while also causing the body's stable immune response. On September 4, The Lancet, one of world's leading medical journals, published a research paper on the results of Phase I and Phase II clinical trials of the vaccine that showed no serious adverse events and an effective immune response of those vaccinated. Requests for more than 1.2 billion doses of Sputnik V vaccine came from over 50 countries. The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries. The existing RDIF contracts with international partners enable the production of 500 million doses of the Sputnik V vaccine outside Russia annually. RDIF is now considering additional requests from a number of countries and companies to further increase its foreign production capacities. On August 11, the Sputnik V vaccine developed by the Gamaleya Center was registered by Russia's Health Ministry and became the world's first registered vaccine against Covid-19. SEE ALSO: <a href="https://www.businessinsider.in/politics/india/news/checkout-here-bihar-assembly-election-2020-results-and-updates-online/articleshow/79142084.cms">Bihar Election Results 2020: Final tally puts NDA in the majority with 125 seats as RJD remains the single largest party</a> <a href="https://www.businessinsider.in/india/news/psu-bank-employees-wage-revision-finalised-after-three-years-of-waiting-only-a-1500-increase-in-salary-for-officers/articleshow/79166497.cms">PSU bank employees wage revision finalised after three years of waiting — only a ₹1,500 increase in salary for officers</a> <a href="https://www.businessinsider.in/tech/apps/news/instagram-down-users-complain-of-frozen-timelines-and-likes/articleshow/79146012.cms">Instagram down for nearly 24 hours— users continue to complain about frozen timelines and likes</a>

Within days of Pfizer results, Russia claims Sputnik V vaccine demonstrates 92% efficacy

New Delhi, Nov 11 (IANS) Russia's National Research Center for Epidemiology and Microbiology and the Russian Direct Investment Fund on Wednesday announced that the Sputnik V vaccine, the world's first registered vaccine against coronavirus created on the well-studied platform of human adenoviral vectors, demonstrated high efficacy. Currently Sputnik V Phase III clinical trials are approved and are undergoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India. A separate detailed study of the vaccine's safety and immunogenicity for elderly people is also being conducted. The confirmation is based on the first interim data from the largest double-blind, randomized, placebo-controlled Phase III clinical trials in Russia involving 40,000 volunteers. The trials evaluated efficacy among over 16,000 volunteers who received the vaccine or placebo 21 days after the first injection. As a result of a statistical analysis of 20 confirmed cases of coronavirus, the case split between vaccinated individuals and those who received the placebo indicates that the Sputnik V vaccine had an efficacy rate of 92 per cent after the second dose. Separately, in September the vaccine was first administered to a group of volunteers from the "red zones" of the Russian hospitals. The observation of additional 10,000 vaccinated volunteers representing medics and other high-risk groups under the civil use of the vaccine out of clinical trials also confirmed the vaccine's efficacy rate of over 90 per cent. The data received will be published by Gamaleya Center researchers in one of the world's leading peer-reviewed medical academic journals following an independent valuation of the data by leading epidemiology experts. Following the completion of Phase III clinical trials of the Sputnik V vaccine, Gamaleya Center will provide access to the full clinical trial report. As of November 11, as part of the clinical trials in Russia's 29 medical centres, more than 20,000 volunteers were vaccinated with the first dose and over 16,000 volunteers with the first and the second dose of the vaccine. In addition, as of November 11, no unexpected adverse events were identified as part of the research. Some of those vaccinated had short-term minor adverse events such as pain at the injection site, flu-like syndrome, including fever, weakness, fatigue, and headache. During the clinical trials, the safety of the vaccine is constantly being monitored; information is analysed by the Independent Monitoring Committee comprising of leading Russian scientists. Collection, quality control and data processing is conducted in line with the ICH GCP standards and involves active participation of Moscow's Health Department and Crocus Medical, the contract research organization (CRO). Observation of the study participants will continue for six months after which the final report will be presented. The research data will be provided by RDIF to the national regulators of countries interested in purchasing the Russian vaccine in order to streamline the registration process. Mikhail Murashko, Minister of Health of the Russian Federation said that the use of the vaccine and the results of clinical trials demonstrate that it is an efficient solution to stop the spread of the coronavirus infection, a preventive healthcare tool, and this is the most successful path to defeat the pandemic. Alexander Gintsburg, Gamaleya Center Director: "The publication of the interim results of the post-registration clinical trials that convincingly demonstrate Sputnik V vaccine's efficacy gives way to mass vaccination in Russia against Covid-19 in the coming weeks. Thanks to the production scale up at new manufacturing sites, Sputnik V vaccine will soon be available for a wider population. This will break the current trend and lead to an eventual decrease in Covid-19 infection rates, first in Russia, then globally." Denis Logunov, Gamaleya Center Deputy Director said that positive interim results of Phase III give reasons to expect a successful outcome of Sputnik V clinical trials. "We will continue to process and analyse all the data and look to the future with optimism, expecting that results of our work will help end the pandemic sooner." Kirill Dmitriev, CEO, Russian Direct Investment Fund: "Sputnik V is the first registered vaccine against Covid-19 in the world, the vaccine is based on a safe and effective platform of human adenoviral vectors. More and more countries are recognising the human adenoviral vector platform and plan to include these vaccines, as the most studied and known, in their respective national vaccine portfolio. I would also like to stress the importance of international cooperation and close partnership among vaccine-developing states." He added, "Vaccines should be above politics. The world needs a diversified portfolio of high-quality vaccines with Sputnik V, based on the well-tested human adenoviral vector platform, being an important element of it." The safety of vaccines based on human adenoviruses was confirmed in more than 75 international publications and more than 250 clinical trials conducted during the past two decades (while the history of use of human adenoviruses in vaccine development started in 1953). Adenovirus vectors are genetically modified viruses of the regular flu that cannot reproduce in a human body. When Sputnik V vaccine is used, the coronavirus itself does not enter the body as the vaccine only contains genetic information about part of its outer protein coat, the so-called "spikes" forming its crown. This completely eliminates the possibility of getting infected as a result of vaccination while also causing the body's stable immune response. On September 4, The Lancet, one of world's leading medical journals, published a research paper on the results of Phase I and Phase II clinical trials of the vaccine that showed no serious adverse events and an effective immune response of those vaccinated. Requests for more than 1.2 billion doses of Sputnik V vaccine came from over 50 countries. The vaccine supplies for the global market will be produced by RDIF's international partners in India, Brazil, China, South Korea and other countries. The existing RDIF contracts with international partners enable the production of 500 million doses of the Sputnik V vaccine outside Russia annually. RDIF is now considering additional requests from a number of countries and companies to further increase its foreign production capacities. On August 11, the Sputnik V vaccine developed by the Gamaleya Center was registered by Russia's Health Ministry and became the world's first registered vaccine against Covid-19. --IANS aka/dpb

You Searched For "alexander gintsburg" and got 9 results

Russia to begin COVID-19 vaccine production within 2 weeks

IANS

3rd stage of Russia's Covid-19 vaccine may begin in 7-10 days

IANS

Russia starts clinical trials of COVID-19 vaccine

PTI

Sputnik V vaccine shows 91.6% efficacy in phase 3 trials, says Lancet

IANS

Sputnik V Covid vax likely to offer 2-year protection: Developers

IANS

Russians have been told not to drink for 2 months after getting the COVID-19 vaccine

Andrea Michelson

Russia says it will start mass-producing its coronavirus vaccine next month — as scientists say developers rushed through tests and injected themselves to shorten human trials

Bill Bostock

Within days of Pfizer results, Russia claims Sputnik V vaccine demonstrates 92% efficacy

IANS

Sputnik V vaccine demonstrates 92% efficacy, claims Russia

IANS

Popular Keywords

Buying Guides